BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261103
DTEND;VALUE=DATE:20261124
DTSTAMP:20260709T125124Z
CREATED:20260709T125124Z
LAST-MODIFIED:20260709T125124Z
UID:43917-1793664000-1795478399@www.pharmajournalist.com
SUMMARY:10th Dermatology Drug Development Summit
DESCRIPTION:10th Dermatology Drug Development Summit – Discovering\, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics – November 3-5\, 2026 | Boston\, MA \nThe 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery\, development\, and commercialization of innovative therapies for inflammatory skin disease. \nMarking a decade of convening the field’s most influential voices\, this year’s summit arrives at a pivotal moment: As competition intensifies across atopic dermatitis and psoriasis\, developers are under growing pressure to demonstrate meaningful differentiation\, accelerate development timelines and identify the next generation of high-value opportunities beyond today’s established targets and therapies. \nDesigned as an intimate\, discussion-led forum\, the summit brings together more than 90 experts spanning discovery\, translational medicine\, preclinical development\, clinical strategy\, medical affairs\, and commercial functions. \nThe meeting provides a unique opportunity to benchmark emerging science\, evaluate novel targets\, and share practical lessons from across the dermatology pipeline. \nAttendees will hear from 40+ senior leaders representing major pharmaceutical companies\, innovative biotechs\, academic research centers\, and patient advocacy organizations\, with representation from AbbVie\, Galderma\, Merck\, SUN Pharma\, Eli Lilly\, UNION Therapeutics and others. \nThis year’s agenda features dual content tracks including Discovery & Preclinical and Clinical & Commercial. \nNew additions include a Pre-Conference Workshop Day\,  offering interactive deep dives into two of dermatology’s fastest-growing areas of innovation: hidradenitis suppurativa\, exploring strategies to drive earlier intervention and disease modification\, and rare & ultra-rare inflammatory skin diseases\, examining how developers can generate meaningful evidence\, overcome translational challenges and unlock scalable opportunities across underserved patient populations. \nWith 10+ hours of in-person networking\, the summit fosters meaningful collaboration among scientists\, clinicians\, executives\, and decisionmakers working to discover\, develop and commercialize the next wave of precision therapeutics. \nFor organizations committed to shaping the future of inflammatory skin disease drug development\, the Dermatology Drug Development Summit remains the essential annual meeting to align on emerging science\, evolving standards of care\, and the path to impactful patient outcomes. \nFind out more about the 10th Anniversary Edition of the Dermatology Drug Development Summit: https://ter.li/rcr0mcj
URL:https://www.pharmajournalist.com/event/10th-dermatology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261116
DTEND;VALUE=DATE:20261118
DTSTAMP:20260805T093959Z
CREATED:20260804T140412Z
LAST-MODIFIED:20260805T093959Z
UID:44087-1794787200-1794959999@www.pharmajournalist.com
SUMMARY:Biomarker Operations & Biospecimen Management Summit
DESCRIPTION:Hot off the press: The biomarker operations and biospecimen community finally has its own dedicated forum. \nIntroducing the inaugural Biomarker Operations & Biospecimen Management Summit\, the industry’s first\, purpose-built meeting for the heads\, VPs and leading stakeholders at pharma and biotech directly responsible for biospecimen and biomarker delivery. \nView the newly released agenda:  https://ter.li/p9sor70u \nWith trials growing in complexity\, rapidly expanding globally and becoming more data-intensive\, biomarker operations has emerged as the critical function for teams looking to advance biomarker- and multi-omics-driven therapies to market. \nAnswering the industry’s call to unite those collecting\, tracking and/or translating biospecimen data\, this meeting arrives at a pivotal moment. \nYou can expect to join 80+ experts to strategize on: \n\nElevating pre-analytical quality and site collection practices\, protecting biomarker signal integrity from the very first draw\nSecuring and storing biospecimens for the long term\, building acquisition\, biobanking\, and disposition strategies that balance cost\, compliance\, and future scientific value\nStreamlining biosample logistics\, kit management and vendor sourcing\, cutting waste and tracking errors so every sample reaches the right lab\, on time\nNavigating consent complexity and evolving regulation\, including IVDR and ICH E6(R3)\, to keep biospecimens compliant and usable for research\, long after collection\nEmbedding FAIR data principles and AI-driven automation into biomarker workflows\, replacing manual reconciliation with systems that accelerate decision-making\n\nAlongside this\, hear best-in-class strategies from AstraZeneca\, Regeneron\, Moderna\, BioNTech\, and Bristol Myers Squibb and real-time updates from Biospecimen Management Consortium (BMC). \nJoin us in collaboratively building the future playbook that will define the standards for precision medicine therapies. \nRegistration is complimentary* for qualifying biopharma and researchers. Visit the website to reserve your spot: https://ter.li/6v47cb7t
URL:https://www.pharmajournalist.com/event/biomarker-operations-biospecimen-management-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261117
DTEND;VALUE=DATE:20261120
DTSTAMP:20260813T160131Z
CREATED:20260813T160131Z
LAST-MODIFIED:20260813T160131Z
UID:44184-1794873600-1795132799@www.pharmajournalist.com
SUMMARY:2nd Model-Informed Drug Development Summit 2026
DESCRIPTION:As model-informed drug development (MIDD) becomes increasingly central to modern drug development strategy\, organizations are under growing pressure to leverage quantitative approaches that accelerate timelines\, reduce risk\, and improve regulatory and clinical success. The 2nd Model-Informed Drug Development Summit\, taking place November 17-19\, 2026\, in Boston\, MA\, brings together senior leaders in pharmacometrics\, clinical pharmacology\, quantitative sciences\, translational medicine\, and regulatory science to explore how modelling is transforming decision-making across the entire development lifecycle. \nDesigned as an intimate and highly interactive forum\, this summit moves beyond traditional large-scale industry meetings to provide meaningful peer-to-peer networking\, practical case studies\, and candid discussions on the real-world challenges of implementing MIDD strategies. Attendees will gain insights from leading organizations including FDA\, Health Canada\, Sanofi\, Eli Lilly\, GSK\, AbbVie\, Novartis\, Amgen\, Genentech\, Gilead Sciences\, BMS\, Astellas Pharma\, Vertex Pharmaceuticals\, Johnson & Johnson\, and Genmab. \nThe agenda explores the latest industry developments\, including implementation of the finalized ICH M15 guideline\, the growing role of quantitative systems pharmacology (QSP)\, advances in AI-enabled modelling\, and the use of real-world evidence to strengthen development decisions. Through case studies\, panel discussions\, workshops\, and roundtable sessions\, attendees will learn how to optimize dose selection\, improve trial design\, accelerate rare disease programs\, validate model outputs\, demonstrate return on investment from MIDD initiatives\, and strengthen regulatory submissions. \nIn addition to the main conference\, dedicated workshops will examine how to integrate pharmacometrics\, QSP\, machine learning\, and AI into connected modelling ecosystems\, while also addressing the challenge of building internal and external stakeholder confidence in modelling approaches. \nWith more than 60 senior industry leaders expected to attend\, the summit offers a unique opportunity to benchmark strategies\, share best practices\, build valuable partnerships\, and stay ahead of evolving regulatory and scientific expectations. Whether you are advancing innovative therapies\, refining quantitative development strategies\, or exploring the future role of AI in drug development\, this event provides the practical insights and connections needed to maximize the impact of model-informed approaches across your organization. \nTo learn more about the event and register online click here.
URL:https://www.pharmajournalist.com/event/2nd-model-informed-drug-development-summit-2026/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261203
DTSTAMP:20260915T005613Z
CREATED:20260811T103702Z
LAST-MODIFIED:20260915T005613Z
UID:44144-1795996800-1796255999@www.pharmajournalist.com
SUMMARY:Novel CNS Biomarkers Summit Europe
DESCRIPTION:Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid\, imaging\, and digital biomarkers for CNS drug development. Bringing together biomarker\, translational medicine\, neuroscience\, and clinical development leaders\, the summit focuses on accelerating the discovery\, validation\, and implementation of next-generation biomarkers across neurodegenerative and neurological diseases. \nAs landmark advances in blood-based Alzheimer’s diagnostics\, digital biomarkers\, multimodal approaches\, and precision medicine continue to reshape the field\, attendees at the Novel CNS Biomarkers Summit Europe will explore strategies to improve patient stratification\, demonstrate target engagement\, generate earlier efficacy signals\, and de-risk CNS drug development programmes. \nCompanies attending the Novel CNS Biomarkers Summit Europe: \n\nRoche\n\n\nUCB\n\n\nLundbeck\n\n\nServier\n\n\nNRG Therapeutics\n\n\nImmunic Therapeutics\n\n\nProgenra\n\n\nSaniona\n\n\nBial\n\n…and more! \nWhy attend the Novel CNS Biomarkers Summit Europe? \n\nJoin 60+ biomarker and translational medicine leaders\n\n\nGain insights from 17+ expert speakers\n\n\nExplore biomarker strategies across 6+ CNS indications\n\n\nParticipate in interactive workshops and networking opportunities\n\nDiscover the brand-new event programme now for more information on sessions and how to register your place.
URL:https://www.pharmajournalist.com/event/novel-cns-biomarkers-summit-europe/
LOCATION:The Hilton London Olympia\, 380 Kensington High St\, Kensington\, London\, W14 8N\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260805T090545Z
CREATED:20260805T090501Z
LAST-MODIFIED:20260805T090545Z
UID:44111-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:8th CNS Drug Delivery Summit
DESCRIPTION:The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system. \nBringing together experts from biopharma\, biotech\, and academia\, the summit will explore the latest advances in drug delivery technologies\, including nanoparticles\, antibody shuttles\, gene therapy vectors\, focused ultrasound\, and intranasal delivery. Attendees will gain practical insights into improving drug penetration\, optimising biodistribution\, and advancing therapies for neurological and neurodegenerative diseases. \nThrough scientific presentations\, case studies\, and interactive discussions\, the event will address key translational\, clinical\, manufacturing\, and regulatory challenges while showcasing innovative approaches that can accelerate CNS drug development. \nJoin a collaborative community of drug developers\, technology innovators\, and scientific leaders committed to unlocking the next generation of CNS therapies and improving outcomes for patients worldwide. \nFind out more today: https://ter.li/08gi5jio
URL:https://www.pharmajournalist.com/event/8th-cns-drug-delivery-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260821T102547Z
CREATED:20260821T102547Z
LAST-MODIFIED:20260821T102547Z
UID:44216-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:4th Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:The 4th Cell Therapy for Autoimmune Disease Summit is the premier industry forum uniting biopharma leaders\, clinical innovators\, and scientific pioneers dedicated to advancing the next generation of cell therapies for autoimmune diseases. As the field progresses beyond early proof-of-concept studies and begins to generate increasingly robust clinical data\, organizations are shifting their focus toward the critical challenges that will determine long-term success. These include identifying optimal targets\, improving clinical translation\, enhancing manufacturing scalability\, ensuring patient safety\, navigating evolving regulatory pathways\, and developing sustainable commercialization strategies. \nTaking place December 1-3\, 2026\, in Philadelphia\, the summit provides a unique opportunity for stakeholders across biotech\, pharma\, academia\, translational research\, and clinical development to come together and share lessons learned from the forefront of autoimmune cell therapy innovation. With increasing momentum behind cell-based approaches for autoimmune indications\, attendees will gain practical insights into how leading organizations are overcoming development hurdles and positioning their programs for future success. \nThe agenda showcases the latest breakthroughs across a range of therapeutic modalities\, including CAR-T\, NK\, Treg\, MSC\, and emerging in vivo cell therapy approaches. Expert speakers from organizations such as Artiva Biotherapeutics\, Kite Pharma\, Cabaletta Bio\, Sail Biomedicines\, Mesoblast\, Orca Bio\, and other leading innovators will present real-world case studies\, clinical updates\, and strategic perspectives. Discussions will focus on analyzing increasingly mature clinical datasets\, expanding cell therapy applications beyond oncology\, exploring novel targets beyond CD19\, leveraging biomarkers and endpoints to optimize development\, and creating scalable manufacturing and delivery strategies to bring therapies to larger patient populations. \nIn addition to its comprehensive scientific program\, the summit offers extensive networking opportunities designed to foster collaboration across the autoimmune cell therapy community. Attendees will have the chance to connect with peers\, potential partners\, investors\, solution providers\, and key opinion leaders who are addressing similar scientific\, clinical\, operational\, and commercial challenges. Through interactive roundtable discussions\, dedicated networking sessions\, and informal meetings\, participants can exchange ideas\, establish valuable partnerships\, and build relationships that help accelerate the development and delivery of transformative cell therapies for patients living with autoimmune diseases. \nTo know more visit: https://ter.li/j0rhnmgf
URL:https://www.pharmajournalist.com/event/4th-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Hilton Philadelphia City Avenue\, 4200 City Ave\, Philadelphia\, PA\, 19131\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260827T093413Z
CREATED:20260827T093413Z
LAST-MODIFIED:20260827T093413Z
UID:44259-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:10th Antifibrotic Drug Development Summit 2026
DESCRIPTION:Antifibrotic Drug Development Summit 2026 | December 1-3\, 2026 | Boston\, MA\, USA \nThe 10th Antifibrotic Drug Development Summit is the industry’s only dedicated forum focused on cross-indication antifibrotic drug development\, bringing together 60+ senior leaders across discovery\, preclinical\, translational\, biomarker\, and early clinical development. \nThis landmark anniversary meeting will explore how shared fibrosis biology\, predictive biomarkers\, human-relevant models\, and fibrosis resolution mechanisms can accelerate the development of next-generation therapies across lung\, liver\, kidney\, cardiac\, skin\, gut\, and systemic fibrosis indications.  \nFeaturing 23+ expert speakers from leading organizations including Madrigal Pharmaceuticals\, AbbVie\, aTyr Pharma\, Pfizer\, Takeda\, Novartis\, Arda Therapeutics\, and Tribune Therapeutics\, attendees will gain actionable insights into target identification\, translational strategies\, patient stratification\, and cross-indication expansion. \nThe event includes our highly anticipated three interactive pre-conference workshops\, two days of scientific presentations\, panel discussions\, and dedicated networking opportunities designed to foster collaboration across the fibrosis ecosystem. \nWho Should Attend? \n\nDiscovery & preclinical scientists\nTranslational researchers\nBiomarker specialists\nClinical development teams\nFibrosis-focused biotech and pharma leaders\n\nRegister and learn more: https://ter.li/5u0tkg56
URL:https://www.pharmajournalist.com/event/10th-antifibrotic-drug-development-summit-2026/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260915T005142Z
CREATED:20260915T005142Z
LAST-MODIFIED:20260915T005142Z
UID:44357-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:Amylin-Based Therapeutics Summit
DESCRIPTION:Amylin‑Based Therapeutics Summit | December 1-3\, 2026 | Boston\, MA\nThe amylin analog space is rapidly expanding in 2026\, with new companies entering the field\, stealth programs beginning to emerge\, and major investment from Roche–Zealand Pharma and AbbVie–Gubra reinforcing growing confidence in the modality. With biology still being unlocked and multiple development paths on the table\, there remains headroom to define best‑in‑class amylin therapeutics\, open new indications\, and shape how this therapeutic area will deliver differentiated\, durable benefit. For companies that get the science right\, the competitive upside is significant. \nThe inaugural Amylin‑Based Therapeutics Summit 2026 arrives at this critical inflection point. This is the first and only industry‑dedicated forum bringing biopharma and academia together to dive deep and explore the full breadth of amylin drug development – from foundational receptor biology to late‑stage clinical strategy. Across two immersive days\, learn from and connect with pioneering minds from Novo Nordisk\, Eli Lilly\, Zealand Pharma\, iBio\, I2O Therapeutics and emerging innovators who are collectively shaping the field. \nView the full event guide: https://ter.li/2ao09t84
URL:https://www.pharmajournalist.com/event/amylin-based-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T155514Z
CREATED:20260813T155514Z
LAST-MODIFIED:20260813T155514Z
UID:44179-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:World CNS Summit South Korea
DESCRIPTION:The World CNS Summit South Korea is the premier industry-focused forum dedicated to advancing targeted\, mechanism-differentiated therapies for neurodegenerative\, rare neurodevelopmental\, and neuropsychiatric disorders. As South Korea emerges as a major center for neuroscience innovation\, the summit convenes biopharma leaders\, translational scientists\, and drug developers to explore the next generation of CNS therapeutics and accelerate progress from discovery through early clinical development. \nThe agenda highlights advances in disease-modifying approaches\, blood-brain barrier delivery technologies\, RNA-based therapeutics\, gene therapies\, neuroinflammation\, biomarkers\, and novel targets beyond traditional amyloid and tau pathways. Attendees will gain insights from leading organizations including ABL Bio\, AriBio\, Johnson & Johnson\, Eli Lilly\, Novartis\, Takeda\, AbbVie\, Lundbeck\, Angelini Pharma and many more. \nDesigned to foster meaningful scientific exchange and strategic collaboration\, the summit provides a valuable platform to connect with Korean biotech innovators\, global pharmaceutical companies\, and external innovation leaders evaluating the next wave of CNS opportunities. For decision-makers shaping neuroscience pipelines\, partnerships\, and licensing strategies\, it offers a focused view of the technologies\, modalities\, and therapeutic approaches driving the future of CNS drug development. \nFind out more today: https://ter.li/jrf94t4n
URL:https://www.pharmajournalist.com/event/world-cns-summit-south-korea/
LOCATION:Grand Hyatt Incheon 208 Yeongjonghaeannam-ro\, 321 Beon-gil\, Yeongjong-gu\, 23358\,  Incheon South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T160546Z
CREATED:20260813T160546Z
LAST-MODIFIED:20260813T160546Z
UID:44189-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:10th Complement-Based Drug Development Summit
DESCRIPTION:The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies\, developers are focused on identifying the right targets\, modalities\, and indications to drive differentiation and patient impact. Recent milestones\, including Regeneron’s cemdisiran advancing through FDA and EMA review and Biogen’s acquisition of Apellis\, highlight the growing momentum and investment shaping the next era of complement therapeutics. \nAs the industry’s only dedicated forum uniting complement leaders\, this meeting will address the strategic and scientific priorities shaping the next generation of complement therapeutics\, including: \n\nAdvancing clinical success through biomarker innovation\, improved target engagement strategies\, robust trial design\, and smarter indication selection to de-risk development\n\n\nBenchmarking next-generation modalities across siRNA\, gene therapy\, biologics\, and novel delivery technologies to improve durability\, efficacy\, safety\, and patient outcomes\n\n\nExpanding beyond C3 and C5 to evaluate intracellular complement biology\, emerging targets\, novel mechanisms\, and combination approaches shaping the next generation of complement therapeutics\n\n\nUnlocking growth beyond renal disease by assessing the translational and clinical opportunity across neurodegenerative\, ocular\, autoimmune\, haematological\, oncology\, and acute indications\n\nWhat to Expect: \n\n80+ Experts Dedicated to Complement\n\n\n18+ Data-Driven Presentations\n\n\n7+ Hours of Meaningful Networking\n\n\n2 Discussion-Led Workshops\n\n\n1 Scientific Poster Session\n\nBringing together biotech innovators\, pharma leaders\, and academic KOLs\, this industry-led anniversary meeting provides a focused opportunity to advance novel targets\, refine modality strategy\, navigate clinical development\, and expand into new indications. \nBy attending\, you’ll be in the room with: Annexon Biosciences\, Apellis Pharmaceuticals\, Cascade Biotechnology\, Complement Therapeutics\, Graviton Biosciences\, Genentech\, Grid Therapeutics\, Ikarovec\, Inflarx\, Regeneron\, Ripple Therapeutics\, Sanofi and more! \nAcross 3 days of discussion-led workshops\, data-driven presentations\, clinical insights\, and expert panels\, engage with the leaders behind renal readouts\, next-generation targets\, and emerging CNS and ophthalmology programs to benchmark your approach\, strengthen differentiation\, and build partnerships that de-risk complement drug development. \nDiscover the 10th Anniversary Meeting program here: https://ter.li/2yscb7oh
URL:https://www.pharmajournalist.com/event/10th-complement-based-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20261106T111814Z
CREATED:20261106T111814Z
LAST-MODIFIED:20261106T111814Z
UID:44712-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:2nd Oligonucleotide-based Therapeutics Summit
DESCRIPTION:The 2nd Oligonucleotide-Based Therapeutics Summit\, taking place from December 8–10\, 2026\, in Boston\, Massachusetts\, will bring together leading scientists\, researchers\, biotech companies and pharmaceutical industry professionals to explore the latest developments in oligonucleotide-based drug development. As RNA-based medicines continue to expand beyond rare genetic diseases into areas such as oncology\, neurology and cardiometabolic disorders\, the summit will provide an important platform to discuss the scientific advances shaping the next generation of therapeutics. \nThe three-day event will focus on key challenges and opportunities in oligonucleotide drug discovery and development\, including extrahepatic delivery\, blood-brain barrier engineering\, advanced oligonucleotide chemistry\, novel conjugates\, circular antisense oligonucleotides (ASOs) and emerging RNA technologies. Attendees will gain insights into new research\, development strategies and innovative approaches to improving drug delivery\, therapeutic effectiveness and pipeline success. \nFeaturing more than 22 expert speakers\, the summit will include technical presentations\, interactive discussions\, dedicated workshops and networking opportunities. Participants will have the opportunity to hear directly from industry experts\, exchange scientific knowledge\, discuss real-world development challenges and learn from the experiences of organisations working across the oligonucleotide therapeutics landscape. \nWith more than 70 industry leaders expected to participate\, the event will provide valuable opportunities for professionals from pharmaceutical and biotechnology companies\, academic institutions and technology providers to build connections and explore potential collaborations. \nWhether working in RNA therapeutics\, antisense oligonucleotides\, drug delivery\, medicinal chemistry\, research and development or preclinical development\, attendees can gain practical insights to help advance their programmes and address key challenges in bringing innovative oligonucleotide medicines closer to patients. \nThe 2nd Oligonucleotide-Based Therapeutics Summit is an important meeting point for professionals looking to understand emerging technologies\, share scientific progress and contribute to the future of oligonucleotide-based medicines. \nTo know more visit: https://ter.li/oi5h1r92
URL:https://www.pharmajournalist.com/event/2nd-oligonucleotide-based-therapeutics-summit/
LOCATION:Aloft Boston Seaport District\, 401-403 D St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261211
DTSTAMP:20261001T143517Z
CREATED:20261001T143450Z
LAST-MODIFIED:20261001T143517Z
UID:44456-1796774400-1796947199@www.pharmajournalist.com
SUMMARY:3rd Obesity & Weight Loss Drug Development Summit West
DESCRIPTION:Optimizing Tolerability\, Quality of Weight Loss & Personalized Therapies to Drive Competitive Drug Development \nAs obesity drug development enters a defining new chapter\, the race is no longer about developing the next GLP-1\, but delivering the next breakthrough in tolerability\, muscle preservation\, patient adherence\, precision medicine\, and long-term outcomes. With hundreds of obesity assets in development and billions of dollars invested in the space\, 2026 is a pivotal moment for companies to differentiate their pipelines\, benchmark their strategies\, and secure their position in the market. \nThe 3rd Obesity & Weight Loss Drug Development Summit West is where the industry’s most innovative pharma and biotech leaders come together to answer the questions that will shape the next decade of obesity therapeutics. While many events focus on clinical readouts or broad discussions around obesity care\, this summit is dedicated to the practical challenges and strategic decisions driving drug development success. \nBringing together 80+ senior executives\, and decision-makers\, this intimate\, industry-focused forum offers unparalleled opportunities to exchange insights\, build meaningful partnerships\, and understand what today’s innovation really means for tomorrow’s therapies. If you’re serious about advancing next-generation obesity therapeutics\, this is the room you need to be in. \nTo know more visit: https://ter.li/hexuee5e
URL:https://www.pharmajournalist.com/event/3rd-obesity-weight-loss-drug-development-summit-west/
LOCATION:Sheraton Mission Valley San Diego Hotel\, 1433 Camino Del Rio South\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270115
DTSTAMP:20261007T105217Z
CREATED:20261007T105217Z
LAST-MODIFIED:20261007T105217Z
UID:44495-1799712000-1799971199@www.pharmajournalist.com
SUMMARY:PFS & Injectable Drug Devices Europe
DESCRIPTION:PFS & Injectable Drug Devices Europe 2027 will bring together pharmaceutical\, biotechnology\, medical device and drug delivery professionals in London from 12–14 January 2027 to explore the latest innovations in pre-filled syringes\, injectable drug delivery devices\, combination products and primary packaging. \nNow in its 19th year\, the conference will provide a focused platform for industry leaders to discuss the technologies\, regulatory developments and market trends shaping the future of injectable drug delivery. The event is designed for professionals working across pharmaceutical development\, drug-device combination products\, medical devices\, pre-filled syringes\, primary packaging\, human factors\, regulatory affairs and manufacturing. \nThe three-day programme will feature presentations and discussions from experts across the pharmaceutical and biotechnology sectors. Key topics will include next-generation pre-filled syringe technologies\, large-volume drug delivery\, novel injectable delivery systems\, device development\, quality by design\, design controls\, human factors and patient-centric drug delivery. \nRegulatory and compliance considerations will also be a major focus\, with sessions exploring combination product regulations\, Article 117\, notified body requirements and evolving European regulatory expectations. These discussions will help companies understand the changing requirements for developing and commercialising injectable drug-device products in Europe. \nThe conference will also examine the growing importance of sustainability in pharmaceutical packaging and drug delivery devices\, including circular economy approaches\, lifecycle carbon assessment and sustainable packaging strategies. \nWith 250+ attendees\, 50+ expert speakers\, interactive roundtables and dedicated networking opportunities\, PFS & Injectable Drug Devices Europe 2027 offers pharmaceutical and biotech professionals an opportunity to share knowledge\, discover new technologies and connect with senior industry decision-makers. \nThe event is particularly relevant for professionals involved in pre-filled syringes\, injectable drug delivery\, combination products\, medical device development\, primary packaging\, pharmaceutical manufacturing\, regulatory affairs and human factors engineering. \nFor more information about the event\, Click Here.
URL:https://www.pharmajournalist.com/event/pfs-injectable-drug-devices-europe/
LOCATION:Marriott Hotel Grosvenor Square\, 10-13 Grosvenor Sq\, London\, W1K 6JP\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:Alessandra.DeMaria@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270115
DTSTAMP:20261110T124032Z
CREATED:20261110T124010Z
LAST-MODIFIED:20261110T124032Z
UID:44736-1799798400-1799971199@www.pharmajournalist.com
SUMMARY:Rational Based Drug Design Summit Europe
DESCRIPTION:The Rational Based Drug Design Summit Europe is the dedicated meeting for structural biologists\, biophysicists\, medicinal chemists\, computational chemists\, AI drug discovery experts and pharma leaders advancing next-generation therapeutics. Join Europe’s leading biopharma organisations to explore how structural biology\, biophysics\, medicinal chemistry and AI are accelerating target identification\, molecular design and candidate selection through case studies\, expert insights and networking opportunities. \nFind out more:  https://ter.li/10npaq8i
URL:https://www.pharmajournalist.com/event/rational-based-drug-design-summit-europe/
LOCATION:Park Plaza Victoria Amsterdam\, Damrak 1-5\, Amsterdam\, 1012 LG\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270122
DTSTAMP:20261002T122815Z
CREATED:20261002T122815Z
LAST-MODIFIED:20261002T122815Z
UID:44487-1800316800-1800575999@www.pharmajournalist.com
SUMMARY:5th Ophthalmic Drug Delivery Summit
DESCRIPTION:The 5th Ophthalmic Drug Delivery Summit is where the innovators behind the next generation of ocular therapies come together to solve one critical challenge: getting the right therapy to the right place in the eye. \nHear directly from leaders at Kodiak Sciences\, Re-Vana Therapeutics\, Ripple Therapeutics\, Eli Lilly\, Genentech\, Sanofi\, Astellas\, Apellis\, Beacon Therapeutics\, Kriya Therapeutics and more as they share the latest thinking on long-acting therapies\, novel delivery routes\, gene and cell therapy\, translational science and drug-device integration. \nWith clinical validation and investment accelerating across the field\, this industry-focused\, modality and indication-agnostic meeting offers a timely opportunity to benchmark emerging technologies\, learn from development successes and setbacks\, and connect with the experts tackling the biggest barriers to effective ocular delivery. \nExpect candid lessons\, emerging strategies and cross-functional perspectives spanning delivery\, formulation\, devices\, CMC\, clinical development\, regulatory strategy and commercialization. \nDon’t miss the only industry-focused\, modality\, and indication-agnostic forum dedicated to ophthalmic drug delivery. \nTo know more visit: https://ter.li/4m4gw2gg
URL:https://www.pharmajournalist.com/event/5th-ophthalmic-drug-delivery-summit/
LOCATION:Hyatt Centric Fisherman’s Wharf San Francisco\, 555 North Point St\, San Francisco\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20260925T061157Z
CREATED:20260925T060703Z
LAST-MODIFIED:20260925T061157Z
UID:44399-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:Muscular Disorders Drug Development Summit
DESCRIPTION:Muscular Disorders Drug Development Summit | January 26-28\, 2027 | Boston\, MA \nThe muscular disease field is entering a pivotal new chapter. Following a year of significant debate around Sarepta’s Elevidys\, the industry is rapidly evolving as a new wave of gene therapies\, RNA medicines\, stem cell therapies\, and small molecules advance through development. With anticipated regulatory milestones from companies including Regenxbio\, Capricor\, and Avidity Biosciences\, alongside growing investment and renewed pharmaceutical interest\, momentum has never been stronger across muscular dystrophies\, Pompe disease\, and related myopathies. \nThe inaugural Muscular Disorders Drug Development Summit is the only industry-focused forum dedicated to helping biopharma leaders accelerate the translation\, clinical development\, and delivery of next-generation therapies for muscle disorders. \nBe the first to access the newly launched event program. \nAcross three days of expert-led presentations\, interactive discussion\, and dedicated networking\, attendees will: \n\nDiscover lessons learned from approved and late-stage muscular disease therapies\nExplore emerging modalities beyond traditional gene therapy\nAdvance biomarker strategies and functional outcome assessments\nInnovate targeted delivery approaches to improve efficacy and reduce off-target effects\nLeverage real-world data to identify meaningful\, patient-relevant endpoints\nBuild partnerships that can accelerate clinical and commercial success\n\nJoin 60+ industry experts and leading organizations including Servier\, Dyne Therapeutics\, Sanofi\, Biogen\, and Avidity Biosciences for three days of collaboration focused on overcoming the biggest challenges in muscular disorder drug development. \nWhether you’re advancing therapies for DMD\, FSHD\, DM\, LGMD\, Pompe disease\, or other rare muscle disorders\, this is the must-attend meeting to benchmark strategies\, forge new partnerships\, and help bring transformative treatments to patients faster. \nExplore the Full Agenda | Register Your Place
URL:https://www.pharmajournalist.com/event/muscular-disorders-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20261007T105805Z
CREATED:20261002T121356Z
LAST-MODIFIED:20261007T105805Z
UID:44484-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:2nd Non-Opioid Pain Therapeutics Summit
DESCRIPTION:One year on from Vertex Pharmaceuticals’ milestone JOURNAVX® approval\, making history as the first new class of pain medicine in decades\, non-opioid pain R&D has skyrocketed as one of biopharma’s hottest areas for innovation and investment\, projected to hit $124bn by 2034. \nBringing together 150+ senior leaders across pain biology\, drug discovery\, translational science\, clinical development\, medical affairs\, business development\, venture capital\, and patient advocacy\, the 2nd Non-Opioid Pain Therapeutics Summit is the ultimate forum for drug developers to advance the next generation of pain medicines. Join experts from Vertex Pharmaceuticals\, Eli Lilly\, AbbVie\, Grünenthal\, Xenon Pharmaceuticals\, Levicept\, Tonix Pharma\, Maxona Pharmaceuticals\, 4E Therapeutics\, NIH\, Harvard Medical School\, and leading investment firms to explore emerging mechanisms\, new clinical data\, trial design innovations\, placebo mitigation strategies\, translational models\, patient-centered development approaches\, and the investment trends shaping the future of pain therapeutics. \nTo know more visit: https://ter.li/9cl7g1gn
URL:https://www.pharmajournalist.com/event/2nd-non-opioid-pain-therapeutics-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270127
DTEND;VALUE=DATE:20270130
DTSTAMP:20261028T115938Z
CREATED:20261028T115938Z
LAST-MODIFIED:20261028T115938Z
UID:44631-1801008000-1801267199@www.pharmajournalist.com
SUMMARY:8th RNAi-Based Therapeutics Summit
DESCRIPTION:The 8th RNAi-Based Therapeutics Summit returns to Boston from January 27-29\, 2027\, bringing together more than 90 industry experts working across oligonucleotide synthesis\, chemistry\, biology\, molecular design\, targeted delivery\, translational development\, and commercialization. The meeting will provide a focused forum for advancing safer\, more potent RNAi therapeutics and expanding their reach beyond traditional liver-directed applications. \nAs investment\, partnerships\, and clinical progress continue to build confidence in RNAi\, extrahepatic delivery remains one of the field’s most significant challenges. The summit will explore how next-generation delivery technologies and oligonucleotide chemistries can improve targeting selectivity\, potency\, durability\, pharmacokinetics\, pharmacodynamics\, and therapeutic index across neurology\, metabolic disease\, obesity\, cardiovascular disease\, kidney disease\, retinal disorders\, oncology\, and other high-value indications. \nAttendees will hear the latest developments in antibody-oligonucleotide conjugates\, aptamer-siRNA conjugates\, nanoparticles\, tetravalent siRNAs\, bispecific RNAi approaches\, cell-specific delivery\, and multi-target silencing strategies. Scientific presentations and panel discussions will examine how developers can cross the blood-brain barrier\, target skeletal muscle and adipose tissue\, deliver genetic medicines to the kidney\, improve retinal gene silencing\, and address complex tumor biology. \nTwo interactive pre-conference workshops will focus on identifying and validating receptors for selective extrahepatic delivery and modifying oligonucleotide chemistry to improve stability\, circulation time\, tissue exposure\, and PK/PD performance. The wider program will also address safety\, clinical translation\, commercialization\, investment\, and strategic partnerships\, helping developers progress promising candidates while reducing technical and commercial risk. \nFeaturing experts from organizations including Sanegene Bio\, Thalia Therapeutics\, Eli Lilly and Company\, Novo\, Bayer\, Bonito Biosciences\, Valaya Bio\, Judo Bio\, UMass Chan Medical School\, and Trinetra Therapeutics\, the summit offers an intimate environment for scientific exchange and meaningful collaboration. Attendees will leave with practical insights and valuable connections to support the development of the next generation of RNAi medicines. \nTo know more visit: https://ter.li/ger5rzdy
URL:https://www.pharmajournalist.com/event/8th-rnai-based-therapeutics-summit/
LOCATION:Homewood Suites by Hilton Boston Seaport District\, 670 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270205
DTSTAMP:20261016T064248Z
CREATED:20261016T064248Z
LAST-MODIFIED:20261016T064248Z
UID:44564-1801526400-1801785599@www.pharmajournalist.com
SUMMARY:2nd Structure-Based Drug Design Summit San Diego
DESCRIPTION:2nd Structure-Based Drug Design Summit San Diego: Advancing Structural Biology\, AI & Emerging Modalities for Next-Generation Drug Discovery \nReturning on February 2-4\, 2027\, the only west coast structural biology event is bringing together structural biologists\, computational chemists\, medicinal chemists\, and drug discovery leaders to explore how cutting-edge structural biology and AI-enabled technologies are transforming modern drug development. \nAs discovery teams face increasing pressure to de-risk pipelines\, tackle hard-to-drug targets\, and accelerate candidate progression\, this summit provides a unique forum to share practical strategies and real-world success stories from across the biopharma industry. \nOver three days of workshops\, presentations\, panel discussions\, and networking\, attendees will gain actionable insights into the integration of AI-driven structure prediction\, de novo protein design\, cryo-electron microscopy (cryo-EM)\, X-ray crystallography\, NMR\, HDX\, SAXS\, and other structural biology techniques. The event focuses on translating high-resolution structural insights into better decision-making\, faster candidate optimization\, and more efficient drug discovery workflows. \nView the full event breakdown here: https://ter.li/3qp8peig \nKey discussion topics include resolving conformational dynamics and cryptic binding pockets\, scaling cryo-EM through automation\, integrating computational and experimental approaches\, advancing predictive modeling\, and applying structure-based drug design (SBDD) to emerging therapeutic modalities such as molecular glues\, PROTACs\, biologics\, peptides\, and protein degradation strategies. \nThe summit features expert speakers and case studies from leading organizations including Pfizer\, Eli Lilly\, Amgen\, Calico Life Sciences\, Denali Therapeutics\, Vilya Therapeutics\, Deep Apple Therapeutics\, Degron Therapeutics\, and many more\, offering attendees the opportunity to learn directly from those at the forefront of structure-guided drug discovery. \nWhether you are looking to improve structure-guided medicinal chemistry\, enhance protein engineering capabilities\, leverage AI more effectively\, or unlock insights into complex biological targets\, the Structure-Based Drug Design Summit San Diego provides an unparalleled opportunity to connect with industry peers\, benchmark approaches\, and discover the latest innovations shaping the future of drug discovery. \nRegister & save today: https://ter.li/o7vi99fl
URL:https://www.pharmajournalist.com/event/2nd-structure-based-drug-design-summit-san-diego/
LOCATION:The Westgate Hotel\, 1055 2nd Ave\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270205
DTSTAMP:20261103T120203Z
CREATED:20261103T120133Z
LAST-MODIFIED:20261103T120203Z
UID:44672-1801526400-1801785599@www.pharmajournalist.com
SUMMARY:LEAP HR Life Sciences Europe
DESCRIPTION:Europe’s life sciences sector is navigating a period of unprecedented change. Funding constraints\, organisational restructuring\, evolving workforce expectations\, and uncertainty around AI’s long-term impact are forcing HR leaders to rethink how they attract\, retain\, develop\, and engage talent. \nReturning for its 9th year\, LEAP HR: Life Sciences Europe is the region’s only industry-specific forum bringing together senior HR leaders from organisations at every stage of growth. With attendees ranging from emerging biotechs preparing for commercialisation\, through to global enterprises managing complex transformations\, this is your unique opportunity to benchmark strategies\, exchange candid lessons learned\, and discover how peers are tackling the talent challenges unique to life sciences. \nThrough interactive discussions\, benchmarking opportunities\, and practical case studies\, gain direct access to fresh perspectives and proven strategies from peers facing similar challenges. You’ll leave this event with not only actionable ideas for workforce planning\, organisational design\, and AI adoption\, but also the trusted connections and ongoing support network needed to accelerate implementation and drive lasting impact within your organisation. \nTo know more visit: https://ter.li/ux78t040
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-europe-2027/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270224
DTSTAMP:20261106T112904Z
CREATED:20261106T112904Z
LAST-MODIFIED:20261106T112904Z
UID:44719-1803254400-1803427199@www.pharmajournalist.com
SUMMARY:SmartLab Exchange Europe 2027
DESCRIPTION:SmartLab Exchange Europe 2027 is the invitation-only forum for senior laboratory\, digital transformation\, data and R&D leaders responsible for accelerating innovation and driving digital transformation across the life sciences and process industries. Bringing together decision-makers from pharmaceutical\, biotech\, FMCG\, food & beverage and chemicals organisations\, the event provides a unique platform to explore the technologies\, strategies and operating models shaping the future of scientific research and development. \nAs organisations seek to operationalise artificial intelligence and advanced digital technologies\, many continue to face challenges including fragmented data environments\, disconnected laboratory systems\, workforce adoption barriers and difficulties scaling AI beyond proof-of-concept projects. SmartLab Exchange Europe 2027 addresses these challenges by focusing on practical\, real-world approaches to achieving successful R&D transformation and delivering measurable business value from digital initiatives. \nThe 2027 programme explores key industry priorities including AI-ready data foundations\, trusted AI governance\, laboratory orchestration\, connected scientific ecosystems\, workforce transformation and the emergence of self-driving laboratories. Through a combination of peer-led case studies\, panel discussions\, think tanks\, interactive roundtables and one-to-one meetings\, attendees will gain actionable insights from organisations successfully implementing AI\, automation and digital innovation across laboratory and R&D environments. \nAttendees will have the opportunity to benchmark their strategies against industry peers\, discover how leading organisations are building scalable AI capabilities\, and explore approaches to improving data quality\, interoperability and digital adoption across the laboratory landscape. The event also examines how organisations can create trusted foundations for AI\, connect previously siloed systems and transform laboratory operations to support faster\, more informed scientific decision-making. \nThe event features senior leaders from organisations including AstraZeneca\, Novartis\, Johnson & Johnson\, Kenvue and Henkel\, alongside an extensive faculty of laboratory\, digital and R&D transformation experts. Designed for leaders shaping the future of laboratory operations and scientific innovation\, SmartLab Exchange Europe 2027 offers a valuable opportunity to exchange best practices\, explore emerging technologies and build the partnerships needed to accelerate product development and unlock the full potential of AI-powered R&D. \nTo know more visit: https://bit.ly/4BHlPdJ
URL:https://www.pharmajournalist.com/event/smartlab-exchange-europe-2027/
LOCATION:Leonardo Royal Hotel Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="IQPC Exchange":MAILTO:enquire@iqpcexchange.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270226
DTSTAMP:20261028T115729Z
CREATED:20261028T115729Z
LAST-MODIFIED:20261028T115729Z
UID:44627-1803340800-1803599999@www.pharmajournalist.com
SUMMARY:3rd Annual TRP Target Selection & Drug Design Summit
DESCRIPTION:The 3rd Annual TRP Target Selection & Drug Design Summit is the industry-dedicated discovery and preclinical forum for advancing the next generation of targeted radiopharmaceutical therapies. Taking place in Boston from February 23-25\, 2027\, the summit will unite more than 100 experts from across discovery\, biology\, medicinal chemistry\, radiochemistry\, ADME/DMPK\, toxicology\, radiobiology\, dosimetry\, preclinical development\, translational science\, and business development. \nAs established targets such as PSMA become increasingly crowded\, the meeting will help radiopharmaceutical developers identify novel targets\, explore new disease settings\, and create differentiated candidates with stronger clinical potential. Attendees will examine how clinically validated targets from ADCs\, RDCs\, immuno-oncology\, and other targeted modalities can be assessed and translated into radioligand therapy programs. \nThe agenda will explore emerging targets across CAIX\, MSLN\, the brain\, extracellular matrix\, and leukocytes\, alongside the biological factors that determine suitability for radiopharmaceutical development. Discussions will also cover targeting moieties\, linkers\, chelators\, radionuclide selection\, biodistribution\, kinetic imaging\, total-body PET\, digital SPECT\, computational biology\, dosimetry\, organ-specific toxicity\, and preclinical safety strategy. \nTwo interactive pre-conference workshops will provide focused learning on using advanced imaging and computational biology to identify high-potential targets\, as well as mining clinical validation from other therapeutic modalities to accelerate target selection. Across the main conference\, presentations\, roundtables\, case studies\, and networking sessions will help attendees benchmark candidate design and determine the evidence required to advance programs confidently toward the clinic. \nWith contributions from experts representing Bayer\, AstraZeneca\, Molecular Partners\, Mariana Oncology\, Harvard Medical School\, United Theranostics\, Ratio Therapeutics\, Affibody\, and other leading organizations\, the summit offers a focused opportunity to improve target selection\, strengthen drug design\, and build safer\, more differentiated radiopharmaceutical pipelines. \nTo know more visit: https://ter.li/ugtcnsbo
URL:https://www.pharmajournalist.com/event/3rd-annual-trp-target-selection-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270224
DTEND;VALUE=DATE:20270226
DTSTAMP:20261110T132343Z
CREATED:20261110T132343Z
LAST-MODIFIED:20261110T132343Z
UID:44746-1803427200-1803599999@www.pharmajournalist.com
SUMMARY:5th Viral Vector Process Development & Manufacturing Summit
DESCRIPTION:The 5th Annual Viral Vector Process Development & Manufacturing Summit brings together leaders across CMC\, process development\, manufacturing\, MSAT\, operations\, and regulatory affairs to advance robust\, reliable\, and reproducible viral vector manufacturing platforms. As the industry shifts towards optimizing proven AAV and LVV platforms\, the summit focuses on overcoming the challenges of scalable manufacturing\, process consistency\, regulatory readiness\, and commercial success. \nThrough real-world case studies\, scientific presentations\, panel discussions\, and networking opportunities\, attendees will explore strategies to improve vector yield\, enhance empty/full capsid separation\, optimize transfection and purification processes\, reduce cost of goods\, and accelerate development timelines through platform-based manufacturing approaches. \nThe summit will showcase practical insights from leading biopharma and biotech organizations including Regeneron\, Sanofi\, Ultragenyx\, Legend Biotech\, Cabaletta Bio\, and Apertura Gene Therapy\, providing attendees with actionable strategies to strengthen manufacturing performance\, improve product quality\, and support successful clinical and commercial outcomes. \nJoin a community of viral vector experts dedicated to increasing productivity\, reducing manufacturing and CMC burden\, and building the scalable processes needed to deliver the next generation of cell and gene therapies. \nFind out more today and secure your complimentary ticket: https://ter.li/2pthcqqz
URL:https://www.pharmajournalist.com/event/5th-viral-vector-process-development-manufacturing-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270312
DTSTAMP:20261103T120728Z
CREATED:20260925T071331Z
LAST-MODIFIED:20261103T120728Z
UID:44434-1804464000-1804809599@www.pharmajournalist.com
SUMMARY:17th World ADC London
DESCRIPTION:17th World ADC London | 8-11th March 2027 | London\, UK\nThe 17th World ADC London will bring together the global ADC community to explore the science\, strategic insights and partnerships shaping the future of antibody-drug conjugate (ADC) development. Taking place from 8-11th March 2027 in London\, the event will bring together more than 700 leaders from biopharma\, biotech\, academia\, investment and solution provider organisations for Europe’s largest annual gathering dedicated to the ADC community. \nAs ADCs continue to gain momentum across oncology\, the industry faces a new generation of challenges and opportunities. From overcoming resistance mechanisms and improving patient response rates to advancing differentiated designs and scaling manufacturing\, the need for collaboration and knowledge-sharing has never been greater. World ADC London provides a platform for the community to exchange ideas\, learn from emerging data and explore the strategies driving the next wave of innovation. \nThe programme spans the full ADC development journey\, covering discovery\, preclinical and translational development\, clinical development\, process and analytical development\, and manufacturing. Attendees will hear from 110 speakers from across Europe\, North America and Asia\, sharing data-driven insights\, case studies and practical approaches across ADC development. \nWith a strong focus on next-generation ADC innovation and differentiation\, the programme will explore approaches including novel cytotoxic and non-cytotoxic payloads\, dual-payload ADCs and bispecific ADCs\, alongside strategies to move beyond established payloads and targets and advance the next generation of ADCs. \nMore than just a scientific meeting\, World ADC London is recognised as an annual meeting point for the global ADC community. For 17 years\, it has brought together established leaders\, emerging biotech companies\, investors and technology innovators in an environment designed to foster meaningful connections and productive discussions. Whether you are looking to benchmark your strategy\, identify new partners\, discover enabling technologies or gain a broader understanding of the competitive landscape\, the event offers opportunities to connect with the people shaping the field. \nWith extensive networking opportunities\, dedicated partnering experiences and cutting-edge scientific content\, World ADC London remains a key forum for those involved in ADC development. Explore the programme to discover the discussions\, emerging data and connections shaping the next chapter of ADC innovation. \nView the agenda here:  https://ter.li/orip0z61
URL:https://www.pharmajournalist.com/event/17th-world-adc-london/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270320
DTSTAMP:20261029T123304Z
CREATED:20261029T123304Z
LAST-MODIFIED:20261029T123304Z
UID:44642-1805241600-1805500799@www.pharmajournalist.com
SUMMARY:11th Liquid Biopsy for Precision Oncology Summit West Coast
DESCRIPTION:The way precision medicine teams design and execute clinical trials today is reshaping the fundamentals of drug development. Teams that have not yet integrated novel liquid biopsy technologies into their programs are already falling behind their peers. \nThe 11th Liquid Biopsy for Precision Oncology Summit West Coast provides a much-needed space to spotlight how pharma are driving liquid biopsy adoption\, whilst addressing the challenges of implementing this powerful new tool across the clinical development lifecycle. \nUniting 250+ biopharma\, diagnostic\, consortia\, academic and patient voices\, this globally renowned meeting continues to house the discussions and collaborations informing the future of the liquid biopsy community. \nSessions will cover dose optimization through to therapeutic monitoring\, patient selection\, multi-omics and beyond\, to ensure your entire team walks away with insights they can apply to their day-to-day role. \nIf you are looking to build the connections and unlock the best-in-class solutions for liquid biopsy application\, this is the room you need to be in. \nWith free* passes available to eligible biopharma and researchers\, don’t pass up the opportunity to join us and the complete West Coast precision medicine community next March. \nTo know more visit: https://ter.li/iod244e2
URL:https://www.pharmajournalist.com/event/11th-liquid-biopsy-for-precision-oncology-summit-west-coast/
LOCATION:Hyatt Regency Mission Bay\, 1441 Quivira Road\, San Diego\, CA\, 92109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270326
DTSTAMP:20261112T123227Z
CREATED:20261112T123227Z
LAST-MODIFIED:20261112T123227Z
UID:44751-1805760000-1806019199@www.pharmajournalist.com
SUMMARY:7th Operationalize: Expanded Access Programs Summit
DESCRIPTION:The 7th Operationalize: Expanded Access Programs Summit returns at a pivotal moment as Expanded Access Programs evolve beyond a purely operational function to become a strategic component of patient access\, evidence generation\, post-trial planning\, and commercial readiness. As organizations expand access into new global markets and face growing expectations around real-world data\, patient continuity\, and reimbursement transitions\, EAP leaders are under increasing pressure to build scalable\, sustainable\, and patient-centric programs. \nAs the industry’s leading forum dedicated to Expanded Access\, this meeting brings together pharma\, biotech\, patient advocacy\, and access leaders to address the most pressing challenges shaping the future of global patient access\, including: \n\nStrengthening global post-trial access strategies to ensure long-term patient continuity while navigating regional regulatory and reimbursement complexities\nLeveraging real-world data generated through Expanded Access to support clinical development\, regulatory strategy\, and future market access decisions\nNavigating complex global access pathways across established and emerging markets while adapting programs to diverse healthcare systems and local requirements\nBuilding sustainable and scalable EAP models through improved governance\, regulatory intelligence\, operational frameworks\, and digital innovation\n\nWhat to Expect: \n\n150+ Pharma\, Biotech & Patient Access Leaders\n20+ Expert Speakers from Takeda\, Regeneron\, Alexion\, Alnylam\, Merck\, Sanofi & More\nInteractive Regional Networking & Peer Benchmarking Sessions\nDedicated Workshops Covering EAP Strategy\, Operations & Post-Trial Access\nLive Problem-Solving Discussions & Access Insights Poster Exchanges\n\nBringing together leaders responsible for medical affairs\, patient access\, clinical operations\, regulatory strategy\, and late-phase development\, this industry-led summit offers a unique opportunity to benchmark approaches\, share practical lessons\, and build meaningful connections with peers navigating the same challenges. \nBy attending\, you’ll be in the room with professionals from Takeda\, Regeneron\, Alexion\, Alnylam\, Merck\, Sanofi\, Sarepta Therapeutics\, Jazz Pharmaceuticals\, Beam Therapeutics\, Amylyx and more. \nAcross three days of workshops\, case studies\, panel discussions\, and networking\, gain practical insights into global access strategy\, post-trial access\, real-world data generation\, reimbursement transitions\, and regulatory intelligence while helping shape the future of Expanded Access Programs. \nDiscover the Full 2027 Agenda Here: https://ter.li/5w26qieq
URL:https://www.pharmajournalist.com/event/7th-operationalize-expanded-access-programs-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270326
DTSTAMP:20261112T125518Z
CREATED:20261112T125300Z
LAST-MODIFIED:20261112T125518Z
UID:44759-1805760000-1806019199@www.pharmajournalist.com
SUMMARY:10th Antigen-Specific Immune Tolerance Summit
DESCRIPTION:The 10th Antigen-Specific Immune Tolerance Summit returns to Boston this March\, bringing together the scientific\, clinical\, and industry leaders advancing antigen-specific therapies for autoimmune disease. \nAs leading programs generate pivotal clinical data and progress toward key development milestones\, the field is entering a new phase of clinical and commercial maturity. The meeting is designed to address the challenges most critical to developers of antigen-specific therapies\, including defining durable tolerance\, identifying meaningful biomarkers\, improving translational success\, optimizing antigen selection\, and generating the evidence needed to support regulatory and investment decisions. \nThe speaker faculty includes leaders from Diamyd Medical\, COUR Pharmaceuticals\, Parvus Therapeutics\, Eli Lilly & Co.\, Pfizer\, Bonsai Biotherapeutics\, and Boehringer Ingelheim\, alongside experts from academia\, investment\, and nonprofit organizations. Attendees will gain practical insights from both preclinical and clinical experience across autoimmune indications\, with discussions spanning development strategy\, biomarker selection\, trial design\, and commercialization pathways. \nView the full program to see what insights you can gain: https://ter.li/5tilo5ny \nKey sessions will explore clinically relevant biomarkers of tolerance\, the predictive value of preclinical models\, monitoring technologies for assessing therapeutic efficacy\, and the growing interest in combination approaches to achieve durable immune tolerance. Dedicated discussions on partnership and investment will also examine the evidence pharmaceutical companies and investors seek when evaluating emerging immune tolerance platforms. \nFor the first time\, the summit will take place as part of World Immune Tolerance Week\, alongside the 9th Treg-Directed Therapies Summit and the 2nd Immune Resetting: B-Cell Mediated & Beyond Summit. This co-located format provides broader visibility into complementary therapeutic approaches and opportunities to connect with decision-makers from across immunology\, autoimmune disease\, and precision medicine. \nSee what the previous attendees have to say: \n“It is truly the annual meeting in the ASIT field\, bringing together a community dedicated to sharing knowledge\, exchanging insights\, and celebrating the advances shaping the field”. \nChief Executive Officer\, Bonsai Biotherapeutics \n“As antigen-specific tolerance rapidly transitions from concept to clinic\, this summit stands out as a unique forum bridging immunology\, bioengineering\, and therapeutic development”. \nInstructor\, Division of Immunology & Rheumatology\, Stanford University \nCo-Founder & Scientific Advisor\, EBVio
URL:https://www.pharmajournalist.com/event/10th-antigen-specific-immune-tolerance-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR